Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16486 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Daniel Martin Simadibrata und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Lansoprazole, Sulfonamides, Pyrroles, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background and Aim Healing rates of severe erosive esophagitis (EE; Los Angeles [LA] Grade C/D) in patients treated with a proton pump inhibitor (PPI) is suboptimal (~60–70%). Vonoprazan, a potassium‐competitive acid blocker, is suggested to have better healing rates in patients with severe EE. This meta‐analysis compares the efficacy and safety of vonoprazan 20 mg versus lansoprazole 30 mg daily in healing EE, specifically in those with LA Grade C/D.
Methods
We searched MEDLINE, Embase, and CENTRAL on May 24, 2023. Studies that randomized EE patients to vonoprazan 20 mg daily or lansoprazole 30 mg daily and compared healing rates were included. The risk of bias was assessed using Cochrane's Risk of Bias 2 tool. The fixed‐effect model was used to obtain the pooled efficacy and safety outcomes. Subgroup analysis was done to compare healing rates in mild (LA Grade A/B) versus severe EE and based on study location.
Results
Four randomized controlled trials (RCTs) with low risks of bias comprising 2208 participants were included. Vonoprazan 20 mg was superior to lansoprazole 30 mg daily in healing severe EE at all weeks (Week 2 RR 1.294 [95% CI 1.169–1.433], Week 4 1.160 [1.059–1.270], and Week 8 1.175 [95% CI 1.107–1.247]), but was similar for mild EE at all weeks ( P ‐interaction < 0.01). Vonoprazan 20 mg was more efficacious than lansoprazole 30 mg at Week 8 in Western versus Asian studies ( P ‐interaction < 0.01). Any, serious, and drug‐related treatment‐emergent adverse events were comparable between groups.
Conclusion
Vonoprazan 20 mg is superior to lansoprazole 30 mg for healing severe EE but not mild EE. Vonoprazan 20 mg daily has a similar safety profile to lansoprazole 30 mg daily.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Division of Gastroenterology and Hepatology, MetroHealth Medical System, Case Western Reserve University, Cleveland, Ohio, USA.
ORCID-Profile: Daniel Martin Simadibrata
Zitieren
APA
Simadibrata, D. M., Lesmana, E., & Fass, R. (2024). Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16486
Vancouver
Simadibrata DM, Lesmana E, Fass R. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16486
BibTeX
@article{Simadibrata2024,
author = {Simadibrata, Daniel Martin and Lesmana, Elvira and Fass, Ronnie},
title = {Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16486}
}
EUVIMED